Results 171 to 180 of about 3,418,997 (346)

Dynamics and challenges of technology transfer in Colombia: a systematic literature review. [PDF]

open access: yesFront Res Metr Anal
Valencia-Arias A   +5 more
europepmc   +1 more source

Thermal Characterization of Biofluids for Heat Transfer Fluid in Thermal Transport Technologies

open access: hybrid, 2021
Lukmon Owolabi Afolabi   +5 more
openalex   +2 more sources

Multinational firms, global value chains and the organization of technology transfer [PDF]

open access: yes
This paper combines insights from different streams of literature to develop a more comprehensive framework for the analysis of technology transfer via value chain relationships. We integrate the existing literature in three ways.
Antonello Zanfei, Federica Saliola
core  

Recurrent cancer‐associated ERBB4 mutations are transforming and confer resistance to targeted therapies

open access: yesMolecular Oncology, EarlyView.
We show that the majority of the 18 analyzed recurrent cancer‐associated ERBB4 mutations are transforming. The most potent mutations are activating, co‐operate with other ERBB receptors, and are sensitive to pan‐ERBB inhibitors. Activating ERBB4 mutations also promote therapy resistance in EGFR‐mutant lung cancer.
Veera K. Ojala   +15 more
wiley   +1 more source

Machine Learning-Derived Correlations for Scale-Up and Technology Transfer of Primary Nucleation Kinetics. [PDF]

open access: yesCryst Growth Des, 2023
Yerdelen S   +9 more
europepmc   +1 more source

Peroxidasin enables melanoma immune escape by inhibiting natural killer cell cytotoxicity

open access: yesMolecular Oncology, EarlyView.
Peroxidasin (PXDN) is secreted by melanoma cells and binds the NK cell receptor NKG2D, thereby suppressing NK cell activation and cytotoxicity. PXDN depletion restores NKG2D signaling and enables effective NK cell–mediated melanoma killing. These findings identify PXDN as a previously unrecognized immune evasion factor and a potential target to improve
Hsu‐Min Sung   +17 more
wiley   +1 more source

Home - About - Disclaimer - Privacy